Opendata, web and dolomites

Savesight SIGNED

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Savesight project word cloud

Explore the words cloud of the Savesight project. It provides you a very rough idea of what is the project "Savesight" about.

diagnose    diurnal    monitoring    stealthy    patents    market    mainly    recognised    treatment    sufficient    hypertension    equal    cure    create    caused    burden    2022    294    permanent    monitorization    life    worldwide    invasive    superior    steadily    significantly    view    angle    sensor    full    billion    gt    intraocular    cycle    accuracy    scientific    algorithms    fraction    overcome    2026    progression    blindness    pending    heavy    technologies    cutting    form    medical    international    healthcare    glakolens    direct    111    ocular    edge    comfort    continuous    safety    enter    revenues    hour    patients    patient    2040    24    iop    prominent    electrical    grow    competitors    single    quality    clinic    conventional    competitor    granted    marketscope    accurately    pressure    plans    glaucoma    elevated    report    reduces    lens    12    chronic    proprietary    million    mechanical    monitor    2021    people    rely    issue    reliability    professionals    contact    aid    indirect   

Project "Savesight" data sheet

The following table provides information about the project.

Coordinator
GLAKOLENS BIYOMEDIKAL BIYOTEKNOLOJISANAYI VE TICARET ANONIM SIRKETI 

Organization address
address: BOGAZICI UNIVERSITY, KUZEY KAMPUS, TEKNOPARK 306, BEBEK YOLU SOKAK 2/5, RUMELI HISARI MAHALLESI
city: SARIYER, ISTANBUL
postcode: 34470
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Turkey [TR]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2020-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLAKOLENS BIYOMEDIKAL BIYOTEKNOLOJISANAYI VE TICARET ANONIM SIRKETI TR (SARIYER, ISTANBUL) coordinator 50˙000.00

Map

 Project objective

Glaucoma affects over 70 million people worldwide (>12 million in Europe), and this number is expected to grow steadily to reach 111 million by 2040. Glaucoma is a chronic condition with no permanent cure and is the second leading cause of blindness. It significantly reduces the quality of life and presents a heavy burden on healthcare systems. Its most prominent and stealthy form, namely open-angle glaucoma, is mainly caused by chronic ocular hypertension (high intraocular pressure [IOP]). Conventional methods used to diagnose elevated IOP, monitor the progression of glaucoma and create treatment algorithms rely on a single IOP measurement conducted at the clinic. Due to the diurnal cycle of IOP, conventional methods do not provide sufficient and reliable information to evaluate the condition of the patients accurately. GlakoLens has been developing a non-invasive contact lens embedded sensor system that will aid medical professionals to overcome this issue by continuous 24-hour monitorization of the IOP changes. GlakoLens' proprietary technology (1 granted and 3 pending international patents) based on years of cutting-edge scientific research enables superior features for the patient (better comfort, electrical and mechanical safety, and full field-of-view) at a fraction of the cost of the only direct competitor in the market while providing better measurement accuracy and reliability. Four more indirect competitors have recognised the need in the market and are developing products using different technologies to address this need. According to a report by Marketscope, IOP monitoring market is expected to reach €1.5 billion by 2021. Glakolens plans to enter the market by the end of 2022, with estimated revenues equal to about €294.6 million in 2026.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SAVESIGHT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SAVESIGHT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

GREEN WHS (2019)

NATURE FRIENDLY WATER HYDRAULIC STEERING SYSTEM

Read More